Skip to main content

Table 1 In vivo efficacy of DOX-SLN and free doxycycline against B. melitensis in acute phase

From: Doxycycline-encapsulated solid lipid nanoparticles for the enhanced antibacterial potential to treat the chronic brucellosis and preventing its relapse: in vivo study

Treatment

Acute stage

CFUs (Log10) in spleen

Log CFUs reduction

CFUs (Log10) in liver

Log CFUs reduction

Untreated

5.03 ± 0.03

0.00

5.05 ± 0.05

0.00

Free SLN

5.02 ± 0.08

0.01

5.04 ± 0.01

0.01

DOX-SLN

4.295 ± 0.27

0.73*

4.30 ± 0.31

0.75*

Free doxycycline

4.301 ± 0.32

0.72*

4.31 ± 0.91

0.74*

  1. Comparisons were performed between all treatments and control without treatment: * P < 0.05
Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us